Search

Shirin Khambata Ford

from Skillman, NJ
Age ~56
Get Report
Also known as:
Shirin K Ford, Shirin R Khambata, Gregory Ford, Ford Shirin Khambata
Phone and address:
9 Jupiter Hills Ct, Montgomery, NJ 08558
Related to:
Ronald M Kleiman, 79Gregory S Ford, 55Jonathan J Kleiman, 50Jennifer L Ford, 49Gregory Ford, 56Christopher T Ford, 55Rustom K Khambata, 60Aford Rd Burton, 80
Connected to:
Adeline C Ford, 90Aeneas Ford, 58Al Ford, 63Alannah A Ford, 29Alena V Ford, 42Alexa L Ford, 76Alissa M Ford, 44Alma Ford, 56Ambi B Ford, 43Ameyia A Ford, 37

Shirin Ford Phones & Addresses

  • 9 Jupiter Hills Ct, Skillman, NJ 08558
  • 45 Jackson Ave, Princeton, NJ 08540 (609) 279-2770
  • Sunnyvale, CA
  • Palo Alto, CA
  • Piscataway, NJ
  • Waldwick, NJ

Publications

Us Patents

Predictors Of Patient Response To Treatment With Egf Receptor Inhibitors

View page
US Patent:
8273534, Sep 25, 2012
Filed:
May 13, 2009
Appl. No.:
12/465503
Inventors:
Joffre B. Baker - Montara CA, US
Drew Watson - Los Altos CA, US
Tara Maddala - Redwood City CA, US
Steven Shak - Hillsborough CA, US
David J. Mauro - Redwood City CA, US
Shirin K. Ford - Redwood City CA, US
Assignee:
Genomic Health, Inc. - Redwood City CA
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C12Q 1/68
US Classification:
435 611, 435 61
Abstract:
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.

Biomarkers And Methods For Determining Sensitivity To Epidermal Growth Factor Receptor Modulators In Non-Small Cell Lung Cancer

View page
US Patent:
20070259375, Nov 8, 2007
Filed:
Mar 28, 2005
Appl. No.:
10/594211
Inventors:
Shirin Ford - Princeton NJ, US
Nancy-Anne Perkins - Lawrenceville NJ, US
Donald Jackson - Lawrenceville NJ, US
International Classification:
G01N 33/53
US Classification:
435007100
Abstract:
EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing a biological sample from the mammal to the EGFR modulator and (b) measuring in the biological sample the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.

Biomarkers And Methods For Determining Sensitivity To Epidermal Growth Factor Receptor Modulators

View page
US Patent:
20100190150, Jul 29, 2010
Filed:
Jan 7, 2005
Appl. No.:
10/585261
Inventors:
Edwin A. Clark - Pennington NJ, US
Shirin K. Ford - Princeton NJ, US
Suganthy Yoganathan - Somerset NJ, US
Donald G. Jackson - Lawrenceville NJ, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.

Biomarkers And Methods For Determining Sensitivity To Epidermal Growth Factor Receptor Modulators

View page
US Patent:
20100221754, Sep 2, 2010
Filed:
Aug 24, 2006
Appl. No.:
11/990713
Inventors:
Shirin K. Ford - Princeton NJ, US
Edwin A. Clark - Pennington NJ, US
Xin Huang - Princeton NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
G01N 33/574
US Classification:
435 723
Abstract:
EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.

Biomarkers And Methods For Determining Sensitivity To Epidermal Growth Factor Receptor Modulators

View page
US Patent:
20120195889, Aug 2, 2012
Filed:
Feb 14, 2012
Appl. No.:
13/372824
Inventors:
Shirin K. Ford - Princeton NJ, US
Edwin A. Clark - Hopkinton MA, US
Xin Huang - Princeton NJ, US
International Classification:
A61K 39/395
C12Q 1/68
A61P 35/00
C40B 30/04
US Classification:
4241331, 506 9, 435 611, 4241381
Abstract:
EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.

Predictors Of Patient Response To Treatment With Egf Receptor Inhibitors

View page
US Patent:
20120270228, Oct 25, 2012
Filed:
Jul 5, 2012
Appl. No.:
13/542323
Inventors:
Joffre B. Baker - Montara CA, US
Drew Watson - Los Altos CA, US
Tara Maddala - Sunnyvale CA, US
Steven Shak - , US
David J. Mauro - Princeton NJ, US
Shirin K. Ford - Princeton NJ, US
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
GENOMIC HEALTH, INC. - Redwood City CA
International Classification:
C12Q 1/68
US Classification:
435 612
Abstract:
The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
Control profile
Shirin Khambata Ford from Skillman, NJ, age ~56 Get Report